Five short months ago, Sangamo (SGMO) released their 2018 results, providing a program review which refocused development priorities. Gene editing trials for hemophilia B, MPS I and MPS II were put on hold. Gene and cell therapies became the more immediate opportunities. Hemophilia A became their lead program followed by gene therapy preclinical programs led by Fabry. The progress seen to date has been compelling. This article will recap the progress reported through the 2Q19 update this past Wednesday. More importantly it will highlight an approach to calculate the value created when